Medicamen Biotech Stock Screener | Share Price & Fundamental Analysis
MEDICAMEQ
Pharmaceuticals
Screen Medicamen Biotech share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹362.25
▼
-5.75 (-1.56%)
Share Price BSE
₹362.35
▼
-4.55 (-1.24%)
Market Cap
₹538.04 Cr.
P/E Ratio (TTM)
57.88
P/B Ratio
1.78
EPS (TTM)
₹5.60
Dividend Yield
0.26%
Debt to Equity
0.15
52W High
₹551.95
52W Low
₹297.00
Operating Margin
11.00%
Profit Margin
4.17%
Revenue (TTM)
₹48.00
EBITDA
₹6.00
Net Income
₹2.00
Total Assets
₹297.00
Total Equity
₹213.00
Medicamen Biotech Share Price History - Stock Screener Chart
Screen MEDICAMEQ historical share price movements with interactive charts. Analyze price trends and patterns.
Medicamen Biotech Company Profile - Fundamental Screener
Screen Medicamen Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for MEDICAMEQ shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE646B01010
Medicamen Biotech Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen MEDICAMEQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Assets | |||||||
| Total Assets | 297 | 295 | 279 | 226 | 194 | 181 | 137 |
| Current Assets | 165 | 160 | 163 | 123 | 96 | 104 | 96 |
| Fixed Assets | 87 | 92 | 93 | 93 | 90 | 34 | 24 |
| Liabilities | |||||||
| Total Liabilities | 297 | 295 | 279 | 226 | 194 | 181 | 137 |
| Current Liabilities | 6 | 3 | 3 | 7 | 8 | 4 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | |||||||
| Total Equity | 213 | 207 | 193 | 147 | 133 | 121 | 87 |
| Share Capital | 13 | 13 | 13 | 12 | 12 | 12 | 12 |
| Reserves & Surplus | 200 | 194 | 178 | 134 | 121 | 109 | 75 |
Screen MEDICAMEQ income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48 | 44 | 35 | 45 | 45 | 44 | 48 | 47 | 44 | 42 | 39 | 36 | 34 | 34 | 23 |
| Expenses | 42 | 38 | 31 | 38 | 39 | 40 | 42 | 42 | 39 | 35 | 32 | 30 | 28 | 27 | 18 |
| EBITDA | 6 | 5 | 4 | 7 | 6 | 4 | 6 | 6 | 5 | 7 | 7 | 7 | 6 | 7 | 5 |
| Operating Profit % | 11.00% | 11.00% | -5.00% | 15.00% | 12.00% | 8.00% | 12.00% | 11.00% | 11.00% | 17.00% | 17.00% | 17.00% | 17.00% | 17.00% | 22.00% |
| Depreciation | 2 | 2 | 1 | 2 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 3 | 2 | 3 | 4 | 2 | 2 | 3 | 3 | 3 | 5 | 4 | 4 | 4 | 4 | 3 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 |
| Net Profit | 2 | 2 | 2 | 3 | 1 | 1 | 2 | 2 | 2 | 4 | 4 | 4 | 4 | 4 | 3 |
| EPS | 1.56 | 1.18 | 1.47 | 2.30 | 0.71 | 0.63 | 1.61 | 1.60 | 1.17 | 3.12 | 3.03 | 2.98 | 2.85 | 2.94 | 2.25 |
Medicamen Biotech Cash Flow Screener - Liquidity Fundamentals
Screen MEDICAMEQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
| Operating Activities | -8 | -7 | -6 | 4 | 13 | 13 | 4 |
| Investing Activities | -1 | -6 | -6 | -9 | -18 | -37 | -15 |
| Financing Activities | -2 | 6 | 29 | 4 | 6 | 19 | -4 |
| Net Cash Flow | -11 | -6 | 17 | 0 | 1 | -5 | -14 |
Screen MEDICAMEQ shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Apr | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 43.16% | 40.46% | 40.46% | 40.46% | 43.21% | 42.99% | 42.99% | 42.99% |
| FII Holding | 0.12% | 0.22% | 0.00% | 0.06% | 0.11% | 0.06% | 0.06% | 0.05% |
| DII Holding | 0.69% | 0.65% | 0.64% | 0.59% | 0.99% | 1.17% | 1.17% | 0.87% |
| Govt Holding | 0.06% | 0.05% | 0.05% | 0.05% | 0.00% | 0.00% | 0.00% | 0.06% |
| Public Holding | 33.35% | 31.58% | 31.50% | 33.35% | 31.95% | 31.57% | 32.43% | 32.96% |
| Other Holding | 22.63% | 27.04% | 27.34% | 25.50% | 23.74% | 24.21% | 23.34% | 23.08% |
| Shareholder Count | 10,435 | 10,592 | 10,808 | 11,177 | 10,639 | 10,652 | 10,792 | 10,576 |
Medicamen Biotech Dividend Screener - Share Yield Analysis
Screen MEDICAMEQ dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.28% |
| 2024-March | ₹1.00 | 0.21% |
| 2023-March | ₹1.00 | 0.26% |
| 2022-March | ₹1.00 | 0.15% |
| 2021-March | ₹1.00 | 0.16% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Medicamen Biotech Index Membership - Market Screener Classification
Screen MEDICAMEQ by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Medicamen Biotech Market Events Screener - Corporate Actions
Screen MEDICAMEQ market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 1.00 /share | -22.18% | ||
| Dividend | ₹ 1.00 /share | 79.23% | ||
| Dividend | ₹ 1.00 /share | -6.07% | ||
| Dividend | ₹ 1.00 /share | -10.33% | ||
| Annual General Meeting | NA | 20.69% | ||
| Dividend | ₹ 1.00 /share | 14.55% | ||
| Annual General Meeting | NA | -9.63% | ||
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 7.40% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -4.93% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.82% |
| 2025-03-26 | 2025-03-26 | Extraordinary General Meeting | NA | -16.66% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 6.85% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -14.31% |
Medicamen Biotech Competitors Screener - Peer Comparison
Screen MEDICAMEQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Medicamen Biotech Company Announcements - News Screener
Screen MEDICAMEQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-07 | Announcement Under Regulation 30 (LODR)- EU Approval For Product Registration Of Paracetamol | View |
| 2025-12-26 | Closure of Trading Window | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Financial Results For The Quarter And Half Year Ended On September 30 2025 | View |
| 2025-11-05 | Board Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Half Year Ended On September 30 2025 | View |
| 2025-10-25 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-27 | Closure of Trading Window | View |
| 2025-09-27 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-26 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-04 | Revised Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) | View |
| 2025-09-04 | Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations) | View |
| 2025-09-03 | Reg. 34 (1) Annual Report. | View |
| 2025-08-13 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-12 | Business Responsibility and Sustainability Reporting (BRSR) | View |
| 2025-08-12 | Outcome Of The Board Meeting Held On August 12 2025 | View |
| 2025-08-07 | Board Meeting Intimation for For Consideration And Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025. | View |
| 2025-07-29 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-06-30 | Closure of Trading Window | View |
| 2025-06-03 | Announcement Under Regulation 30 (LODR)- Approval Of Abbreviated New Drug Application (ANDA) | View |